EMA has 67 days to decide whether to back recommendation of its expert committee
Amryt
Dublin-based biopharma group says most of the funds to be used to repay existing loan
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
Company upgrades forecasts as it completes Chiasma takeover
Drug group expands its portfolio of medicines while reporting first-quarter numbers
Group plots dual Nasdaq listing to create enlarged rare disease company
Lojuxta revenues driven by UK, France reimbursement approval
Biopharma firm signs new deal for gene therapy that could treat genetic condition EB
Most Read
You may also like...
Crosswords & puzzles to keep you challenged and entertained
Start The Search For Your Next Job
Audio versions of the best journalism from The Irish Times